Literature DB >> 10595952

Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease.

A Mager1, S Lalezari, T Shohat, Y Birnbaum, Y Adler, N Magal, M Shohat.   

Abstract

BACKGROUND: Homozygosity for the common (677C-->T) mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is associated with hyperhomocysteinemia, but there is uncertainty as to the association between this mutation and coronary artery disease (CAD). This study examined the association between MTHFR genotypes and age at onset of CAD. METHODS AND
RESULTS: Patients (n=169) with documented myocardial infarction or angiographically documented CAD who were aged < or = 55 years at onset of CAD symptoms and DNA samples from control subjects (n=313) were studied. The prevalence of homozygosity among patients with early CAD onset (aged < or = 45 years) was 28%, which was significantly higher than that in patients with later onset (13%) and in control subjects (14%) (odds ratio 2.4, 95% CI 1.24 to 4.69, P=0.006, and odds ratio 2.7, 95% CI 1.15 to 6.42, P=0.01, respectively). Plasma folate was lower in TT homozygotes who had early CAD onset than in those with later onset (P=0.005). Among patients with plasma folate in the lowest quintile (< or = 12.6 nmol/L), 31% were homozygotes, as were 45% of those with low plasma folate and early CAD onset. There was no difference in the prevalence of traditional risk factors among genotypes. The frequency of homozygosity in patients with < or = 1 risk factor was higher than in those with > or = 2 risk factors (30% versus 12%, P<0.05). In multiple regression analysis, TT homozygosity and plasma folate were independently associated with CAD, but the impact of folate was small.
CONCLUSIONS: Homozygosity for the 677C-->T mutation of MTHFR is common and is associated with an increased risk of premature CAD in this population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595952     DOI: 10.1161/01.cir.100.24.2406

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Prevalence of the methylenetetrahydrofolate reductase 677C > T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors.

Authors:  M Guillén; D Corella; O Portolés; J I González; F Mulet; C Sáiz
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 3.  Hyperhomocysteinemia and thrombosis.

Authors:  M Cattaneo
Journal:  Lipids       Date:  2001       Impact factor: 1.880

4.  Association of MTHFR C677T (rs1801133) and A1298C (rs1801131) Polymorphisms with Serum Homocysteine, Folate and Vitamin B12 in Patients with Young Coronary Artery Disease.

Authors:  Rajni R Shivkar; Gayatri C Gawade; Meghana K Padwal; Arundhati G Diwan; Sumiran A Mahajan; Charushila Y Kadam
Journal:  Indian J Clin Biochem       Date:  2021-05-18

5.  Age-related alteration of risk profile, inflammatory response, and angiographic findings in patients with acute coronary syndrome.

Authors:  Hala Mahfouz Badran; Mohamed Fahmy Elnoamany; Tarek Salah Khalil; Mostafa Mohamed Ezz Eldin
Journal:  Clin Med Cardiol       Date:  2009-02-18

6.  A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis.

Authors:  Rogelio Palomino-Morales; Carlos Gonzalez-Juanatey; Tomas R Vazquez-Rodriguez; Luis Rodriguez; Jose A Miranda-Filloy; Benjamin Fernandez-Gutierrez; Javier Llorca; Javier Martin; Miguel A Gonzalez-Gay
Journal:  Arthritis Res Ther       Date:  2010-04-26       Impact factor: 5.156

7.  Molecular genetics of myocardial infarction.

Authors:  Yoshiji Yamada; Sahoko Ichihara; Tamotsu Nishida
Journal:  Genomic Med       Date:  2008-08-14

8.  Association of polymorphism in the thermolabile 5, 10-methylene tetrahydrofolate reductase gene and hyperhomocysteinemia with coronary artery disease.

Authors:  Mohammad A Alam; Syed A Husain; Rajiv Narang; Shayam S Chauhan; Madhulika Kabra; Suman Vasisht
Journal:  Mol Cell Biochem       Date:  2007-12-12       Impact factor: 3.396

9.  Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease.

Authors:  Paul Williams; Lakshmana Pendyala; Robert Superko
Journal:  BMC Med Genet       Date:  2011-03-24       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.